Condition

Locally Advanced Solid Tumor

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14
Recruiting4
Common interventions25
Lead sponsors shown14
Advertisement

Clinical trials

14 shown
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid TumorsNCT06975410 · 2025-06-12
RECRUITING
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsNCT05732831 · 2023-05-26
RECRUITING
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)NCT06028724 · 2023-05-26
RECRUITING
FOG-001 in Locally Advanced or Metastatic Solid TumorsNCT05919264 · 2023-05-23
RECRUITING
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 MutationNCT05919537 · 2023-09-06
ACTIVE_NOT_RECRUITING
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid TumorsNCT05268666 · 2022-04-08
UNKNOWN
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437 · 2022-03-15
TERMINATED
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesNCT05081609 · 2022-01-11
ACTIVE_NOT_RECRUITING
Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibNCT04770688 · 2020-11-19
COMPLETED
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid TumorsNCT04383210 · 2020-09-29
TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersNCT04260802 · 2020-09-24
TERMINATED
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsNCT04319757 · 2020-06-24
COMPLETED
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesNCT03881488 · 2019-05-17
COMPLETED
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsNCT01390818 · 2011-05-01
COMPLETED

Trial status mix

COMPLETED4
RECRUITING4
TERMINATED3
ACTIVE_NOT_RECRUITING2
UNKNOWN1

Phase mix

PHASE111
PHASE29
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.